LQDA Stock Analysis: Buy, Sell, or Hold?
LQDA - Liquidia Corporation Common Stock
$76.43
0.94 (1.24%)
▲
5d:
+6.44%
30d:
+23.33%
90d:
+115.28%
WAIT
LOW Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Smart Money Distribution
None View Scanner →
Strength: 8.3/10
Get Alerted When LQDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: LQDA is 11.1% above its trading range ($68.79). Market expects 5.8% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: LQDA is 11.1% above its trading range ($68.79). Market expects 5.8% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$124.78
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$77.48
1.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LQDA is currently trading at $76.42, which is considered extended relative to its 30-day fair value range of $58.05 to $68.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 13.6) compared to its historical average (11.5). At these levels, the market is pricing in 5.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LQDA is in a strong uptrend. The price is approaching resistance at $76.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LQDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $66.12. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LQDA is in a strong uptrend. The price is approaching resistance at $76.66. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LQDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. However, the stock is trading significantly above the average Wall Street target of $66.12. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$58.05 -
$68.79
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
41.9%
Protect Your Profits
LQDA is technically overbought (RSI 74). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+11.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 12.4% above Wall St target ($66.12)
- NEUTRAL: Trading at premium valuation - market expects 5.8% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$58.05 -
$68.79
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$61.72
Resistance Level
$76.66
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.55
Wall Street Target
$66.13
(-12.4%)
Revenue Growth (YoY)
4158.5%
Profit Margin
7.7%
Valuation Premium vs History
+5.8% premium
PE vs Historical
13.6 vs 11.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.8%
(market-implied from PE analysis)
1-Year Target
$79.87
(+6%)
2-Year Target
$84.50
(+12%)
3-Year Target
$89.40
(+18%)
3-Yr Target (if PE normalizes)
(PE: 14→12)
PE COMPRESSION
$75.89
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 60.1%)
$409.58
(+443%)
Base:
(SPY PE: 13.5, Growth: 60.1%)
$254.78
(+238%)
Bear:
(PE: 11.5, Growth: 60.1%)
$216.26
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Forward PE: 34.25 | Forward EPS (Implied): $2.20
Bull Case
$91.15
(+21%)
Analyst growth 15.0%, PE expands to 36.0
Base Case
$75.49
(0%)
Market implied 0.0%, PE stable at 34.3
Bear Case
$57.75
(-24%)
Severe decline -15.0%, PE contracts to 30.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 10:17 AM ET
Data refreshes hourly during market hours. Next update: 11:17 AM
Data refreshes hourly during market hours. Next update: 11:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LQDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Roger Jeffs
SELL
18839 shares
2026-04-17
Michael Kaseta
SELL
139390 shares
2026-04-15
Roger Jeffs
SELL
25000 shares
2026-04-15
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 61 BUY |
Advanced LQDA Option Strategies
Professional options setups generated by AI based on today's LQDA price and gamma walls.